Biocogniv

1. The organization requires FDA marketing authorization at the time of purchase

   • If procurement requires an AI sepsis diagnostic that already has FDA marketing authorization, consider vendors that document De Novo or other authorization pathways; Biocogniv’s public milestone is Breakthrough Device Designation, which is not the same as marketing authorization.

2. The organization requires abundant third-party reviews and benchmarks before purchase

   • Biocogniv has limited accessible presence on major review platforms; organizations that require extensive public customer feedback and third-party evaluations may prefer vendors with broader public review footprints.

3. The organization prioritizes minimizing external vendors and relies on Epic-native tooling

   • Epic customers may prefer native models to reduce vendor management, contracting, and integration effort.

4. The organization has low tolerance for integration/validation effort

   • Any AI that uses lab/vital pipelines and real-time inference typically requires local validation and monitoring; organizations unable to support that work may find integration burdensome.

5. The organization requires strict, publicly documented security certifications (SOC 2 Type II / ISO 27001) prior to contracting

   • Public materials accessed do not document SOC 2 Type II or ISO 27001; procurement may require those attestations before proceeding.

Sources:

• https://www.biocogniv.com/post/biocogniv-receives-fda-breakthrough-designation-for-sepsis-aimarker-tm
• https://prenosis.com/news/prenosis-announces-fda-de-novo-marketing-authorization-of-immunoscore/

• Breakthrough Device Designation is a regulatory interaction pathway and does not equate to marketing authorization; further regulatory steps may be required for the intended clinical use.

Source:

• https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program

• Routine lab-based AI biomarkers: The vendor describes the product as using routinely ordered lab tests as model inputs.
• FDA Breakthrough Device Designation for Sepsis aiMarker (vendor-announced regulatory interaction signal).
• Reported scale of underlying dataset: The vendor reports extensive real-world datasets (e.g., reported counts of patient encounters and laboratory results on its website).

Critical notes:

• The vendor-reported dataset size and other scale metrics are not independently audited in the accessed sources.
• Breakthrough Device Designation denotes a prioritized FDA interaction program and is not equivalent to regulatory clearance or marketing authorization.

Sources:

• https://www.biocogniv.com/
• https://www.biocogniv.com/post/biocogniv-receives-fda-breakthrough-designation-for-sepsis-aimarker-tm
• FDA Breakthrough program explainer: https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program

• Prenosis: public FDA marketing authorization for a sepsis AI diagnostic and distribution channel via Roche navify.
• Epic: native EHR integration reduces integration overhead for Epic customers.

Sources:

• https://prenosis.com/news/prenosis-announces-fda-de-novo-marketing-authorization-of-immunoscore/
• https://navify.roche.com/us/en-us/marketplace/products/algorithms/navify-algorithms-sepsis-immunoscoretm-by-prenosis

The company’s website includes vendor-published testimonials attributed to clinicians and healthcare innovation stakeholders. These endorsements express favorable impressions of the product’s capability to use routine laboratory tests for earlier identification of patients at risk of sepsis and reference clinical validation activity. These are vendor-selected endorsements and should be considered in that context.

Examples of attributed endorsers (paraphrased):

• W. Frank Peacock, MD: cited on the vendor site as expressing a favorable view of using routine blood tests for earlier detection.
• Joshua Tamayo-Sarver, MD PhD (Vituity): cited on the vendor site as characterizing the vendor’s approach as an advancement beyond traditional alerting approaches.
• Peter McCaffrey, MD (UTMB): cited on the vendor site as noting agreement between independent validation results and expected performance.

These vendor-published endorsements are signals of clinician engagement but are not a substitute for broad, independently collected customer feedback about implementation burden, false positive management, and long-term operational outcomes.

Biocogniv published work on an AI model for COVID-19 detection/rule-out using routine blood tests, including references to validation across multiple hospitals and a peer-reviewed publication.

• This indicates technical capability and collaboration with clinical partners.
• It is not equivalent to evidence from commercial sepsis product deployments with sustained operational outcomes.

Sources:

• Official vendor blog post referencing a peer-reviewed publication and validation work
• Industry press release covering validation claims

The vendor’s April 7, 2023 announcement includes performance-style summary statistics, for example:

• within the first few hours of ED presentation, flagging a substantial share of encounters that later developed severe sepsis without satisfying SIRS criteria at prediction time
• flagging a substantial share of encounters that received later sepsis intervention at a later timepoint after the prediction

Critical evaluation:

• These figures are vendor-published and are not accompanied in public materials by full study design details, denominators, site characteristics, PPV/NPV, calibration, or subgroup performance reporting.
• Flagging rates alone do not demonstrate clinical benefit without information on false positives, actionability, and workflow integration.
• Breakthrough Device Designation indicates the FDA provided prioritized interaction under its program; it is not equivalent to clearance or authorization.

Source:

• Vendor announcement / company blog post about the Breakthrough Device Designation

A CMS NTAP applicant tracking form (FY2026) lists Biocogniv Inc and Sepsis aiMarker as technology used to aid in identifying patients at risk for having or developing sepsis.

Critical evaluation:

• This indicates an intent to pursue reimbursement mechanisms.
• It does not guarantee NTAP approval, actual payment levels, or demonstrable hospital financial return on investment.

Source:

• Official CMS NTAP applicant tracking forms (public documentation)

Given the enterprise acute-care nature, Biocogniv likely fits:

• Company size: Hospitals and health systems, often mid-size to large (e.g., hospitals with substantial inpatient capacity, multi-hospital systems)
• Clinical setting: EDs with high volumes where earlier recognition could materially affect ICU admissions and patient outcomes
• Digital maturity: Organizations with established health IT / interface teams and clinical informatics governance

Biocogniv is a clinical AI / "digital diagnostics" company focused on acute-care prediction and early detection (especially in Emergency Department workflows) using routine clinical inputs (not novel lab assays). Its primary product, Sepsis aiMarker™, is an AI-based software device intended to identify patients with sepsis (or at risk of developing sepsis) earlier than standard clinical recognition—using routine laboratory panels and vital signs—to support earlier clinical recognition and potential intervention. The company also describes a broader platform, clinOS™, that integrates with hospital systems and processes ongoing laboratory results. (Vendor statements.)

Biocogniv’s marketing materials and vendor statements state objectives such as:

• predicting time-critical conditions earlier (vendor-stated phrasing includes "before they become irreversible")
• using routine clinical tests already performed in hospitals
• building and using real-world datasets for evidence generation

Sources: Official vendor documentation; Regulatory press release.

• Primary customers: Hospitals and health systems (especially ED / acute-care settings), with stakeholders likely spanning ED physicians, hospitalists, intensivists, nursing leadership, quality/safety leaders, and lab/pathology informatics.
• Positioning: The vendor describes the product as a "digital diagnostic" rather than a generic early warning alert; the vendor refers to "AI biomarkers" derived from routine laboratory tests.

Sources: Official vendor documentation; Market intelligence profiles.